» Articles » PMID: 28426788

Association Between Hemoglobin Glycation Index with Insulin Resistance and Carotid Atherosclerosis in Non-diabetic Individuals

Overview
Journal PLoS One
Date 2017 Apr 21
PMID 28426788
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Hemoglobin glycation index (HGI), defined as the difference between the observed HbA1c value and the value of HbA1c predicted from plasma glucose levels, represents a measure of the degree of non-enzymatic glycation of hemoglobin and it has been found to be positively associated with micro- and macro-vascular complications in subjects with type 2 diabetes. To investigate the pathophysiological abnormalities responsible for the increased cardiovascular risk of patients with higher HGI, we evaluated the association of HGI with cardio-metabolic characteristics in nondiabetic offspring of type 2 diabetic individuals. Insulin sensitivity, measured by a hyperinsulinemic-euglycemic clamp, cardio-metabolic risk factors including lipid profile, uric acid and inflammatory factors, and ultrasound measurement of carotid intima-media thickness (IMT) were assessed in 387 nondiabetic individuals. Participants were stratified in tertiles according to HGI (high, moderate and low). As compared with subjects with low HGI, those with high HGI displayed an unfavorable cardio-metabolic risk profile having significantly higher values of BMI, waist circumference, triglycerides, uric acid, fasting insulin, inflammatory markers, such as high sensitivity C reactive protein, erythrocytes sedimentation rate, complement C3, fibrinogen, and white blood cell count, and carotid IMT, and lower HDL and insulin-stimulated glucose disposal. In a linear regression analysis model including several atherosclerotic risk factors such as gender, age, BMI, inflammatory factors, lipid profile, insulin-stimulated glucose disposal, fasting insulin, uric acid, and blood pressure, HGI was the major predictor of IMT (β = 0.35; P = 0.001). In a logistic regression analysis adjusted for confounders, individuals with high HGI showed a 2.7-fold increased risk of vascular atherosclerosis (OR 2.72, 95%CI 1.01-7.37) as compared with subjects with low HGI. The present findings support the notion that HGI may be a useful tool to identify a subset of nondiabetic individuals conceivably harboring a higher risk of cardiovascular disease.

Citing Articles

Association between glycation gap and impaired cardiorespiratory fitness: evidence from American adults.

Fei M, Wu B, Tu J, Chen H, Guo Y BMC Cardiovasc Disord. 2025; 25(1):119.

PMID: 39979808 PMC: 11840999. DOI: 10.1186/s12872-025-04578-y.


A genome-wide association study identifies genetic determinants of hemoglobin glycation index with implications across sex and ethnicity.

House J, Breeyear J, Akhtari F, Evans V, Buse J, Hempe J Front Endocrinol (Lausanne). 2024; 15:1473329.

PMID: 39530122 PMC: 11551017. DOI: 10.3389/fendo.2024.1473329.


Association of hemoglobin glycation index with clinical outcomes in patients with coronary artery disease: a prospective cohort study.

Wen Z, Li F, Wu T, Hou X, Pan Y, Deng C Diabetol Metab Syndr. 2024; 16(1):241.

PMID: 39367504 PMC: 11451236. DOI: 10.1186/s13098-024-01475-w.


Association of haemoglobin glycation index with all-cause and cardiovascular disease mortality in diabetic kidney disease: a cohort study.

Huang L, He L, Luo X, Zhou X Diabetol Metab Syndr. 2024; 16(1):221.

PMID: 39261957 PMC: 11389330. DOI: 10.1186/s13098-024-01462-1.


Glycated haemoglobin index is a new predictor for all-cause mortality and cardiovascular mortality in the adults.

Huang Y, Huang X, Zhong L, Yang J Sci Rep. 2024; 14(1):19629.

PMID: 39179628 PMC: 11343730. DOI: 10.1038/s41598-024-70666-2.


References
1.
Rojas A, Perez-Castro R, Gonzalez I, Delgado F, Romero J, Rojas I . The emerging role of the receptor for advanced glycation end products on innate immunity. Int Rev Immunol. 2013; 33(1):67-80. DOI: 10.3109/08830185.2013.849702. View

2.
Yudkin J, Forrest R, Jackson C, Ryle A, Davie S, GOULD B . Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia. 1990; 33(4):208-15. DOI: 10.1007/BF00404798. View

3.
Herman W, Ma Y, Uwaifo G, Haffner S, Kahn S, Horton E . Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30(10):2453-7. PMC: 2373980. DOI: 10.2337/dc06-2003. View

4.
Kilpatrick E, Maylor P, Keevil B . Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care. 1998; 21(2):261-4. DOI: 10.2337/diacare.21.2.261. View

5.
Kilhovd B, Juutilainen A, Lehto S, Ronnemaa T, Torjesen P, Birkeland K . High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005; 25(4):815-20. DOI: 10.1161/01.ATV.0000158380.44231.fe. View